Market Access

Faster launch planning leads to greater access.

The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.

Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.

The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.

A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.

Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.

A focus on medical affairs and medical science liaisons.

Pandemic-reinforced principles of successful drug launch.

In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.

A business framework for pricing and broader brand strategy.

Commercial-model shift demanding greater influence of these teams.

David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.

Identifying unique traits in patients is key to creating the most effective support programs.

Writing at the intersection of managed markets and the pharmaceutical industry.

On examination of the challenge and strategies, lack of adherence is in and of itself a preventable disease.

Winning in the 20s: How access needs to evolve.

Patient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.

Taking a closer look at the evolving legal treatment of coupons and copay accumulators.

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

If telehealth is here to stay, how is the industry adjusting?

How technology can maximize use of manufacturer copay and patient assistance programs.

The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.

A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.

Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.